2 chapters across the catalog
Chronic Weight Management, FDA Terminology and Rat Studies
An examination of the FDA's use of the term "chronic weight management" for Zepbound. The drug's safety warnings include the risk of thyroid C-cell tumors observed in rat studies, though the implications for human health remain officially unknown.
Lorcaserin Weight Loss Drug, Arena Pharmaceuticals
Arena Pharmaceuticals is developing Lorcaserin, a new oral drug for weight management currently in Phase 3 clinical trials known as BLOOM and BLOSSOM. The drug targets obesity through behavioral modification and chemical intervention. Skepticism is expressed regarding the long-term safety of such weight-loss pills, noting a history of similar drugs being found deadly after release.
